Document is current
Any future updates will be listed below
-
Authors
Kim, David D.
Barr, Alasdair M.
Lian, Lulu
Yuen, Jessica W. Y.
Fredrikson, Diane
Honer, William G.
Thornton, Allen E.
Procyshyn, Ric M. https://orcid.org/0000-0002-4348-0855
- License Information
-
More Information
Article History
Received: 5 November 2020
Accepted: 21 April 2021
First Online: 25 May 2021
Competing interests
: A.M.B. has no potential conflicts. W.G.H. has received consulting fees or sat on paid advisory boards for the AlphaSights, Guidepoint, In Silico (unpaid), Newron, Translational Life Sciences and Otsuka/Lundbeck, and is a shareholder in Eli Lilly and Translational Life Sciences. R.M.P. has received consulting fees or sat on paid advisory boards for Janssen, Lundbeck and Otsuka; is on the speaker’s bureau for Janssen, Lundbeck and Otsuka. D.D.K., L.L., J.W.Y.Y., D.F. have no conflict of interest to declare.
